
When someone is faced with a cancer diagnosis and treatment, they often wonder “do I need to go out on disability?” Unfortunately, they aren’t always sure what that actually means, or that it could mean multiple things.

When someone is faced with a cancer diagnosis and treatment, they often wonder “do I need to go out on disability?” Unfortunately, they aren’t always sure what that actually means, or that it could mean multiple things.

In life, sometimes we are surprised beyond belief. There are three times in my life when having cancer made me think, "Wait! What?"

The Healing Net Foundation gathers patients, caregivers and health care providers to collaborate in raising awareness and educating the medical community about an underserved disease: neuroendocrine tumors.

Merger combines more than 30 years of patient-centered expertise to "Empower Everyone, Ignore No One."

Merger combines more than 30 years of patient-centered expertise to "Empower Everyone, Ignore No One."

A recent clinical trial is examining the combination regimen of netupitant plus palonosetron (NEPA), with hopes that it can curb nausea and vomiting both before and after chemotherapy in patients with peripheral T-cell lymphoma, Hodgkin lymphoma, mantle cell lymphoma and diffuse large B-cell lymphoma.

The expenses of cancer far extend what is covered by insurance, and the damage it can do can forever alter the life of a young adult with cancer.

An expert discusses how CAR-T cells will fit into the treatment paradigm for patients with multiple myeloma in the future.

Becoming a caregiving to a loved one with cancer feels as if my life has been turned upside down like a snow globe and I am left to hold on to the stable anchors.

In a follow-up post, one survivor explores the use of CBD products and shares how they've helped manage her post-cancer pain.

From today’s top entertainers and athletes to a ban on implants linked to cancer, here’s what is making headlines in the cancer space this week.

Although a reasonable and often curative treatment option, use of allogeneic hematopoietic stem cell therapy in relapsed multiple myeloma still tends to fall under the radar.

A model that calculates the probability of cancer may help to rule out a lung cancer diagnosis following screening preventions – which would substantially reduce false positives.

The FDA has expanded the approval of Ibrance (palbociclib) capsules in combination with endocrine therapy for male patients with hormone receptor (HR)–positive, HER2-negative advanced or metastatic breast cancer.

We've got a sneak peek at what’s inside CURE®'s Women’s Cancers issue.

An expert discusses treating multiple myeloma with potential curative intent.

Create a digital health binder, improve communication, find clinical trials and get connected with three free mobile apps.

An expert discusses new treatment options for patients diagnosed with CLL.

Vice President Joe Biden discusses ways to work collectively with the Biden Cancer Initiative to explore gaps in cancer detection and treatment, identify solutions to address them and inject the urgency of now to make progress.

Patients with previously treated, advanced NSCLC who received Opdivo therapy experienced a survival benefit over many years, according to a pooled analysis of four studies.

This breast cancer and melanoma survivor encourages newly diagnosed cancer patients to hang onto their hope.

Patients with relapsed or refractory chronic lymphocytic leukemia may have more options now than ever before, according to William G. Wierda, M.D., Ph.D.

Susan G.Komen-Greater NYC announced today the members of its newly appointed Medical Advisory Committee.

Sometimes it takes a bigger candle to shine a light on our disease.

The PAN Foundation today opened a new patient assistance program for people living with Waldenstrom macroglobulinemia, a rare type of blood cancer that originates in the lymphatic system and is characterized by an excess of abnormal white blood cells and proteins called immunoglobulins.

While novel agents continue to evolve in the treatment landscape for chronic lymphocytic leukemia, many may start to be combined in the front-line setting as well, according to Matthew S. Davids, M.D., MMSc.

As much as patients look forward to the day they can ring the bell or hear they have no evidence of disease, it can also mean they will be sent out on their own to sort through life with the long-term damage of cancer.

Liquid biopsies may be less invasive and faster in determining the genetics of a tumor — and with high accuracy — among those diagnosed with non-small cell lung cancer.

The National Community Oncology Dispensing Association, Inc. (NCODA) is pleased to announce the addition of three new members to the Executive Council.

Here are the top 5 CURE stories for March 2019.